
    
      Part 1 is a dose-escalation phase with a 3+3 sequential-group design in which patients will
      receive a dosimetry dose followed by maximum of two 5-week cycles of treatment doses of
      intracerebroventricular 177Lu-DTPA-omburtamab.

      Part 2 is a cohort-expansion phase in which patients will receive a maximum of five 5-week
      cycles of intracerebroventricular 177Lu-DTPA-omburtamab at the recommended dose determined in
      Part 1.

      End of treatment will take place within 5 weeks after the last cycle and thereafter the
      patients will be enter the follow-up period. The patients will be followed for up to 2 years
      after last dose.
    
  